http://localhost:8080/xmlui/handle/123456789/7539 2026-04-09T05:47:45Z 2026-04-09T05:47:45Z Akhmal Muslikh, Faisal Adi Priatna, Puja Ekasari2, Wiwied http://localhost:8080/xmlui/handle/123456789/7552 2024-11-08T02:24:52Z 2023-04-30T00:00:00Z

Title: Pharmacological Effects of Glycyrrhiza glabra L. as Antihepatitis and Hepatoprotective for Children Authors: Akhmal Muslikh, Faisal; Adi Priatna, Puja; Ekasari2, Wiwied Abstract: Abstract Background: The incidence of hepatitis in children has grown from the normal number of hepatitis cases since January 2022, and it will continue to rise since the etiology and pathophysiology are unknown. This case is distinct from those caused by the hepatitis A, B, C, D, and E viruses. Glycyrrhiza glabra L. is a medicinal herb that has long been used in medicine to treat respiratory, digestive, and immune system problems, but it is also known to have an inhibitory impact on the virus. Coronavirus-associated acute respiratory syndrome, hepatitis, herpes simplex virus, influenza virus. Objective: This article will look at Glycyrrhiza glabra L.'s antihepatitis and hepatoprotective properties. Methods: The Pubmed, Sage Journal, and Sciencedirect databases were searched using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards and the keywords "Glycyrrhiza glabra for hepatitis." The inclusion and exclusion criteria were followed. Results: From the search results, 17 publications were discovered that explain how Glycyrrhiza glabra L. can operate as an antihepatitis agent through anti-inflammatory, antiapoptotic, and hepatoprotective mechanisms. Conclusion: Glycyrrhiza glabra L. can be used as an anti-hepatitis and hepatoprotective in children at doses ranging from 240-480mg/kg/day. Keywords: Glycyrrhiza glabra, Licorine, Pediatric Hepatitis, Hepatoprotective, Toxicity.

2023-04-30T00:00:00Z Ja’far Shodiq, Muhammad Hartono, Farmindo Khaerunnisa, Siti Machin, Abdulloh http://localhost:8080/xmlui/handle/123456789/7551 2024-11-08T02:20:46Z 2023-04-30T00:00:00Z

Title: Analysis of Potential Cinnamomum zeylanicum Blume Essential Oil Against Alzheimer’s Disease: A Molecular Docking Study Authors: Ja’far Shodiq, Muhammad; Hartono, Farmindo; Khaerunnisa, Siti; Machin, Abdulloh Abstract: Abstract Background: Alzheimer's Disease (AD) is a neurodegenerative disorder with progressive impairment of behavioural and cognitive functions and the most common cause of dementia. The pathophysiology of AD is associated with low acetylcholine, accumulation of amyloid beta plaque, and neurofibrillary tangles in the brain. Cinnamomum zeylanicum is known to have many medicinal properties, especially neuroprotective effects. Objective: This research was designed to determine the neuroprotective potential of the phytochemicals C. zeylanicum using an in silico study. Methods: There are 5 phytochemicals compounds of C. zeylanicum used in this study. It's qualified for Lipinski’s rules of five and can cross blood brain barrier. The protein targets were AChE, BACE1, and GSK-3. Molecular docking and visualization were performed using Avogadro, AutoDock 4.2 PyMol and Biovia Discovery Studio 2019. Results: In silico results show that the main phytochemical compounds of C. zeylanicum Blume essential oil have great potency as an AD drug. The best interaction model of the compound was shown by trans-cinnamyl acetate and coumaric acid. Although the binding energy of the compounds is lower than AD drugs (donepezil, rivastigmine, galantamine), the binding energy is not much different from rivastigmine and galantamine. Conclusion: The phytochemical compounds of C. zeylanicum Blume essential oil have an effect as a neuroprotective agent for AD and should be investigated in future research. Keywords: Alzheimer’s Disease, Cinnamomum zeylanicum, Molecular Docking Study

2023-04-30T00:00:00Z Mardiyanto, Mardiyanto Fitria Apriani, Elsa Kalingga Jati, M. Pandu http://localhost:8080/xmlui/handle/123456789/7550 2024-11-08T02:19:41Z 2023-04-30T00:00:00Z

Title: In Vitro Release Ability of Nanoparticles Poly-Lactic-Co-Glycolic-Acid (PLGA) Gel Containing Pegagan Leaves Ethanolic Extract (Centella asiatica L.) Authors: Mardiyanto, Mardiyanto; Fitria Apriani, Elsa; Kalingga Jati, M. Pandu Abstract: Abstract Background: Pegagan (Centella asiatica L.) leaves are proven to contain high concentrations of flavonoid compounds as antioxidants. Flavonoids are unstable compounds due to environmental influences such as light, humidity, pH, and oxygen. The stability of pegagan extract was proven to be improved by making the extract into nanoparticle preparations. Objective: This study aims to formulate nanoparticles of pegagan into gel preparations and determine their release ability with the Franz diffusion test using a cellophane membrane compared to pegagan gel not formulated into nanoparticles. Methods: Nanoparticles were made using poly-lactic-co-glycolic acid polymers and then formulated into gels with various concentrations of Carbopol 934, namely 1, 1.5 and 2%. The gel nanoparticles were then subjected to the characterization of the preparation, stability test and release test of the preparation. Results: A concentration of 1% Carbopol 934 provides the best evaluation of gel preparations where the gel produced was homogeneous, pH was around 6.2, viscosity was 3417.12 cPs, spreadability was 5.1 cm, and adhesion was 209.33 seconds. The stability test showed no significant organoleptic and pH changes (p>0.05). The release kinetics model occurs at zero order. F1 has a higher reaction kinetics constant (k) than the other formulations, so drug release occurs faster. Conclusion: The best formula of pegagan (F1) nanoparticle gel was proven to have good physical stability and release ability. Keywords: Centella asiatica L; Nanoparticles; Gel; Franz Diffusion

2023-04-30T00:00:00Z Junita Miru, Seisye Libriansyah, Libriansyah Mufarrihah, Mufarrihah Nita, Yunita http://localhost:8080/xmlui/handle/123456789/7549 2024-11-08T02:17:04Z 2023-04-30T00:00:00Z

Title: Cost of Illness Study in Thyroid Patients: A Systematic Review Authors: Junita Miru, Seisye; Libriansyah, Libriansyah; Mufarrihah, Mufarrihah; Nita, Yunita Abstract: Abstract Background: The thyroid has a vital role in growth, neurodevelopment, reproduction, and metabolism. About 300 million people around the world had been reported to be suffering from thyroid disorders, but more than half were unaware. The factors of sex, age, weight of disease, and other accompanying conditions should be considered, otherwise, it will cause a long time treatment period in which the cost will become higher from year to year. Purpose: The systematic review aims to provide an overview of the financial burden caused by thyroid disease for the communities, governments and health care providers. Method: A systematic review of publications in several databases, namely PUBMED, SCIENCE DIRECT, DOAJ, SCOPUS and GOOGLE SCHOLAR. Results: Six research articles were obtained from publications selected for systematic review. The reviewed articles show overviews of the cost of thyroid disease in several countries. The financial burden of thyroid patients in some countries varies, with different perspectives. The lowest to highest cost ranges from 0.125 USD/patient – 8106 USD/patient. Conclusion: The study in this review illustrates the various costs in different countries; the cost of screening, and thyroid surgery has the largest contribution compared to other costs; research on the financial burden suffered by thyroid patients in the future must be carried out continuously and periodically to be able to estimate the cost of therapy more appropriately to provide a useful data for health care providers, governments and the community. Direct medical costs are the largest proportion. Keywords: thyroid, cost of disease, cost analysis, the economic cost burden

2023-04-30T00:00:00Z